Intravenous Ferric Carboxymaltose (Ferinject) in Patients Undergoing Orthopaedic Surgery

Inclusion Criteria: * age \>= 18 years * Patients scheduled to undergo hip or knee replacement * 8 g/dl \< Hb \< 13 g/dl for men and 8 g/dl \< Hb \< 12 g/dl for women at screening (3-4 weeks prior to surgery) * anemia * signed written informed consent Exclusion Criteria: * immunosuppressive or myelosuppressive therapy * history of thromboembolic events * a concurrent medical condition(s) that would prevent compliance or participation or jeopardize the health of the patient * hypersensitivity to any component of the formulation * transfusion within 1 month prior to study inclusion * liver values 3 times higher than normal * active severe infection/inflammation * renal insufficiency